Threshold halting enrollment in clinical trial

Redwood City biopharmaceutical firm Threshold Pharmaceuticals Inc. (THLD) will stop enrollment in a Phase 2 clinical trial evaluating the use of glufosfamide in patients with recurrent, sensitive small cell lung cancer.

The first stage of the trial, which included 21 patients, showed only one confirmed partial response. Under the design of the trial, three or more responses were required before an additional 29 patients would have been enrolled.

Patients already enrolled will be given the option to continue in the trial.

businessBusiness & Real Estate

If you find our journalism valuable and relevant, please consider joining our Examiner membership program.
Find out more at www.sfexaminer.com/join/

Just Posted

Pandemic exacerbates food insecurity for San Franciscans in need

Mayor Breed proposes $45.7 million for meal programs under two-year budget

Doing No Harm: Ahimsa Sumchai

Doctor tracks health of Bayview residents affected by toxins from former shipyard

Francis Ford Coppola to turn part of landmark Columbus Tower into boutique hotel

Famed ‘Godfather’ director speaks about North Beach plans at local hearing

‘Major surge’ in COVID-19 cases prompts plans for Presidio medical site

SF diagnosing an average of 98 new coronavirus cases daily

Most Read